Navigation Links
Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry

MIAMI--(BUSINESS WIRE)--Jun 21, 2007 - Answerthink, Inc. (NASDAQ: ANSR) announced today that it has formed a strategic alliance with LORENZ Life Sciences Group for the distribution of LORENZ solutions in North America. Answerthink and LORENZ Life Sciences Group will serve midsize companies by integrating best practice submissions management solutions into Answerthink's Life Science solutions based on SAP technology.

Answerthink's pre-configured EzLifeSciences solutions are designed specifically to help midsize companies streamline new product development, automate manufacture reporting, and meet regulatory compliance requirements. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management for regulated environments within the life sciences industry as well as supporting the FDA mandate to submit electronically by the end of 2007.

"We are delighted to be able to tap into Answerthink's North American sales and service infrastructure, as well as their unrivaled SAP solution and deployment knowledge in the Life Sciences industry," said Wolfgang Witzel, President of LORENZ Life Sciences Group.

"This is a welcome confirmation of the global reputation we have acquired since 1989 in the field of submission management," added Mr. Witzel, stating that "the solutions we have provided to our customers and the results they have achieved are indeed - best practice."

According to Answerthink SAP Solutions Group Managing Director John McGrath, "We're delighted to be working with LORENZ. Our EzLifeSciences solutions are providing superior value for growing, innovative customers. LORENZ has successfully developed purpose-built solutions that can be integrated at ease which will only enhance our offerings to this industry."

About Answerthink

Answerthink, Inc. (www.answerthink.com) is a leading business and technology consulting firm that ena
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera

Post Your Comments:
(Date:11/6/2009)...Mass., Nov. 6 Facet Solutions, Inc...assets of Archus Orthopedics. The acquisition crea...fferings, intellectual property and clinical exper... win for patients suffering from lumbar spinal ste...O, Geoff Pardo. "This consolidation further stren...
(Date:11/6/2009)...anitoba, Nov. 6 With his proposed ...s set his sights on cutting name-brand prescriptio...ho fall into the "Part D" coverage gap, universall...bout the potential cost-cutting and feel it,s a pr...he most powerful lobbyists want a revised program ...
(Date:11/6/2009)...v. 6 GeoVax Labs, Inc. ...any"), an Atlanta-based, biopharmaceutical company...HIV-1 (Human Immunodeficiency Virus) and other inf...2009 financial results and provided an operational...d Chief Executive Officer commented, "We are pleas...
Breaking Medicine Technology:Facet Solutions Acquires Archus Orthopedics 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8ReBuilder Medical Technologies Inc Announces First Quarter 2009 is Profitable 55336 1ReBuilder Medical Technologies Inc Announces First Quarter 2009 is Profitable 55336 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 1Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 3Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 4Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 5Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 6Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 7Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 8HPV Vaccine Could Prevent Many Penile Cancers 55330 1HPV Vaccine Could Prevent Many Penile Cancers 55330 2
...(TM) HBSAG Test Found to Have Higher Sensitivity a...FirstVue(TM) ,...and was the preferred ... SPRINGS, Fla., Oct. 13 AT First Diagnostic LLC a...gnostic test kits, today,announced that a recent e...ute of Research of the FirstVue(TM) HBSAG Test, wa...
...n of Genomic DNA from Multiple Cancer Populations ...dies, ANN ARBOR, Mich., Oct. 13 Rubicon Genomics...erick to amplify DNA samples for The,Cancer Atlas ... amplify and standardize total genomic,DNA from 3,... The Rubicon,GenomePlex(TM) Whole Genome Amplifica...
Other Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3
(Date:11/8/2009)...ut position promotes self-assurance, research find... Your mother may have been right when she told you...od posture could make you feel more confident abou...t sitting up straight gives a good impression to o...y and a psychology professor at Ohio State Univers...
(Date:11/8/2009)... 8 Speaker Nancy Pelosi...llowing the House passage of H.R. 3962, the Afford... by a vote of 220 to 215. Below are the Speaker,s...ues just received a call from the President of the... a great victory for the American people. I thank ...
(Date:11/8/2009)... Freeze-drying of biopharmaceuticals to be avai...facility. , Toronto, ON ...ent and CEO of Therapure Biopharma Inc. today anno...mercial scale pharmaceutical grade freeze dryer an...lyophilization) available for contract manufacturi...
(Date:11/8/2009)...es not mean the battle is won," said Dr. Charmaine...wswire/ -- In a vote of 240-194, the Stupak-Ellswo...nt to prohibit abortion mandates and funding in HR...nited for Life Action President and CEO Dr. Charma...a victory for the pro-life Americans across this c...
(Date:11/8/2009)... Passage of H.R. 3961 to Secure the Stability of M...ire/ -- Statement Attributable to: J. James Rohack..., (Logo: http://www.newscom.com/cgi-bin/prnh/...age of the House health reform bill, which will he...icians and calls for swift passage of H.R. 3961 to...
Breaking Medicine News(10 mins):Health News:Good Posture May Inspire Confidence 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2
...LANSING, Mich., March 6 Accident Fund Insurance C...y as a 2007 recipient of its,President,s Club Awar...0070827/CLM117LOGO ), The award is presented eac...ume and profitability goals for the,previous year....
...Young Boston woman shares story of firstborn son,s...thing,s wrong with your baby.", Words a pregnant ...ays,that "something" is called an omphalocele, whi... Sarah Doyle, 29, and her 32-year-old husband Mike...
..., Philadelphia, PA, March 6, 2008 Surgeons are u...ent in patient care and to develop innovative solu... productive surgical researchers may lack the know...ary 2008) provides surgeons with expert insights i...
..., APS-1 is an rare hereditary disease where the i...the framework of a major EU project, coordinated b...tists have now managed to identify a protein that ...ngland Journal of Medicine. , The newly discovere...
..., HOBOKEN, N.J. A 10-pound rodent pest called nu...as been especially damaging to the marshland ecolo...ita and Katrina, may have finally met its match th...vens Institute of Technology in Hoboken, New Jerse...
...50-year-old Beverly Hills Cowboy pledges to fund $...ldren,s Hospital, Los Angeles, BEVERLY HILLS, Cal...as home to the rich and famous but in the midst of...ills for most of his life and was,introduced to th...
Other Medicine News:Health News:You're Not Alone: How Mothers of Children Born with Rare Condition Comfort and Support Each Other on CarePages.com 2Health News:You're Not Alone: How Mothers of Children Born with Rare Condition Comfort and Support Each Other on CarePages.com 3Health News:You're Not Alone: How Mothers of Children Born with Rare Condition Comfort and Support Each Other on CarePages.com 4Health News:'Surgery' looks at inventions and innovations by surgeons 2Health News:New protein discovery helps researchers understand autoimmune diseases 2Health News:Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands 2Health News:Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands 3Health News:Beverly Hills Executive Competes as a Rodeo Cowboy to Fund Cancer Research 2Health News:Beverly Hills Executive Competes as a Rodeo Cowboy to Fund Cancer Research 3
SonoSite MicroMaxx
25-Hydroxy Vitamin D RIA
Roche/STAGO STA Compact
Roche/STAGO STA-R Evolution®
Medicine Products: